PSA evolution: A prognostic factor during treatment of advanced prostatic carcinoma with total androgenic blockade. Data from a Belgian multicentric study of 546 patients

Acta Urologica Belgica

Volumn 65, Issue 3, 1997, Pages 63-65

  Oosterlinck, W ^a   Mattelaer, J ^a   Casselman, J ^a   Van Velthoven, R ^a   Derde, M P ^a   Kaufman, L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

hormonal treatment; progression free survival; prostatic carcinoma; PSA

Indexed keywords

FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROGNOSIS; PROSTATE CARCINOMA;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BELGIUM; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HEALTH STATUS; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ORCHIECTOMY; PAIN; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SAFETY; SURVIVAL RATE; URINATION DISORDERS;

EID: 0030659642     PISSN: 00017183     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)